Presenter's Information

David R. Holmes, MD

Country USA
Specialty Interventional Cardiologist
  1. Moderators\' Introductory Keynote: Why This Debate So Controversial?
  2. Overtreatment in Cardiology in 2018! What Is Reasonable?
  3. PCI vs. CABG for Left Main in 2018 - Expert\'s View on U.S. Future Guideline Change
  4. WATCHMAN: Data Synthesis and Ongoing Trials
  5. [Special Lecture] Stroke Prevention in Non-Valvular Atrial Fibrillation
  6. Future Perspective on LM Revascularization: From Evidence to Real Practice
  7. Bioprosthetic Valve Thrombosis(TAVR & SAVR)
  8. LAA Occlusion for Stroke Prevention: What Is the Ideal?
  9. TAVI for Combined CAD
  10. How Should LAA Closure Devices Be Integrated into Clinical Practice?
  11. Practical Experience: Longterm Results and Obstacles
  12. Guideline Today: Focus on the Culprit!
  13. Update on TAVR Results 2014
  14. Left Atrial Appendage Closure: Clinical Data and Future Perspective
  15. Left Atrial Appendage Occlusion: Results and Future Predictions
  16. Update on LAA Closure Devices: Will They Get Approved?
  17. Update on PROTECT AF
  18. Viable Role in ACS or PCI Patients: Combination of Anticoagulant and Antiplatelet Is Still Attractive Approach.
  19. STICH: Physician\'s Perspective
  20. The SYNTAX Message Is Clear: CABG Is Preferred in Complex Multivessel Disease
  21. Differential Treatment Effects of PCI vs. CABG in Diabetic and Non-Diabetic Patients
  22. Coronary Intervention
  23. Revascularization Strategies (SYNTAX, BARI-2D, and STICH)
  24. Revascularization in Diabetes: New Insights from the BARI 2D
  25. Timing of Angiography after NSTEMI. Now, or a Little Later, or Only If Needed?
  26. No More Routine Surgery!
  27. PROTECT AF Trial: Randomized Prospective Trial of Percutaneous LAA Closure vs Warfarin for Stroke Prevention in AF
  28. [Debate] Which one Is the Best Choice in Left Main Revascularization?: : PCI Is the Best Choice.
  29. In-Stent Restenosis: The Last Achilles' Hill to Still Conquer
  30. Do DES Increase or Decrease Mortality for "On-Label" and "Off-Label" Use Indications?
  31. DES Thrombosis: Is It Real and Is It Worse? New Approaches to Solving It ?
  32. The Preponderance of Data Favors CYPHER!
  33. SISR. A Prospective Randomized Comparison of the Sirolimus-Eluting Stent vs Brachytherapy in Patients with Bare Metal In-Stent Restenosis
  34. THE GREAT DEBATE : All Patients Should Receive a Drug Eluting Stent - CON
Conference Slides
Category